Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes
Primary and study completion pushed from Apr 2026 to Nov 2026
University of Illinois at ChicagoPhase 2 NCT03121014 Registry history of NCT03121014 on ClinicalTrials.gov (opens the registry)